How to score the impact of treatment on cutaneous neurofibromas in clinical trials
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljad492 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Nicolas Ortonne. Beteiligte Einrichtung: Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibroma, Connective Tissue Diseases, Skin Neoplasms. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Most patients with neurofibromatosis 1 (NF1) develop a variable number of cutaneous neurofibromas (cNFs) which have a major impact on patients’ quality of life0. A major problem is how to score the response to therapy in clinical practice and trials. A measurement instrument recognized by all experts in the field is required to be able to judge the efficacy of treatments and the benefits perceived by the patients. Fertitta and colleagues propose a system for assessing cNFs severity and impact with a list of items validated by a consensus of experts and patients.This qualitative approach has the advantage of integrating multiple parameters of interest, based in part on a “patient-centric” approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital.
- Université Paris Est Créteil.
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, Créteil, France.
ORCID-Profile: Nicolas Ortonne
Zitieren
APA
Ortonne, N. (2024). How to score the impact of treatment on cutaneous neurofibromas in clinical trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad492
Vancouver
Ortonne N. How to score the impact of treatment on cutaneous neurofibromas in clinical trials. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad492
BibTeX
@article{Ortonne2024,
author = {Ortonne, Nicolas},
title = {How to score the impact of treatment on cutaneous neurofibromas in clinical trials},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljad492}
}
EUVIMED